Status:

COMPLETED

A Study to Evaluate the Pharmacokinetics of Duloxetine in Chinese Han Healthy Subjects

Lead Sponsor:

Shanghai Mental Health Center

Collaborating Sponsors:

Jiangsu Nhwa Pharmaceutical Co., Ltd.

Conditions:

Healthy

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

The primary objective of this study is to evaluate the pharmacokinetics of duloxetine hydrochloride tablets in Chinese Han Healthy Subjects. The single oral dose and multiple oral dose of the drug in ...

Detailed Description

This is an open, parallel assignment (low-dose, moderate-dose and high-dose), inpatient, sequential-group pharmacokinetics study of single oral administered and multiple oral administered to healthy C...

Eligibility Criteria

Inclusion

  • Healthy Chinese Han male or female determined by the investigator on the basis of medical history and physical examination
  • Age from 18 to 45 years old at screening
  • Body mass index (BMI) from 19\~24 kg/m2 and body weight ≥ 50 kg at screening
  • Normal clinical laboratory test results or 'no clinical significantly abnormal' results judged by the investigator at screening
  • Subjects can comply with all requirements of the study according to study procedure
  • A sighed and dated ICF (informed consent form) with approval by IEC

Exclusion

  • Participation in any drug trial within 1 month prior to enrollment into this study
  • Known hypersensitivity to duloxetine hydrochloride or relative compounds
  • Abnormal 12-lead electrocardiogram (ECG) results and increasing risk to participate this study determined by investigator
  • Presence or history of any medical disorder, including cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, psychiatric and neurologic system, or medical conditions that would significantly affect the absorption, distribution, metabolism, or excretion of investigational drug, or increase risk to administer investigational drug, or interfere explanation for data
  • History of hepatitis B and/or HBsAg (+)
  • Serum HIV antibody (+) or hepatitis C Antibody (+)
  • Female subjects of childbearing potential with a positive human chorionic gonadotropin (HCG) test or lack of a reliable method of contraception
  • History of blood donor within 3 months prior to enrollment
  • History of drug abuse or alcoholism
  • Use any drugs including traditional Chinese Medicine within 1 week prior to enrollment
  • Any unsuitable subjects judged by the investigator

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2009

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT00933452

Start Date

July 1 2009

End Date

December 1 2009

Last Update

June 15 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China, 200030